RU2460540C2 - Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk) - Google Patents

Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk) Download PDF

Info

Publication number
RU2460540C2
RU2460540C2 RU2008146922/10A RU2008146922A RU2460540C2 RU 2460540 C2 RU2460540 C2 RU 2460540C2 RU 2008146922/10 A RU2008146922/10 A RU 2008146922/10A RU 2008146922 A RU2008146922 A RU 2008146922A RU 2460540 C2 RU2460540 C2 RU 2460540C2
Authority
RU
Russia
Prior art keywords
antibody
alk
seq
sequence
variable region
Prior art date
Application number
RU2008146922/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2008146922A (ru
Inventor
ДЕР МАУР Адриан АУФ (CH)
ДЕР МАУР Адриан АУФ
Петер ЛИХТЛЕН (CH)
Петер ЛИХТЛЕН
Олсайд БАРБЕРИ (CH)
Олсайд БАРБЕРИ
Original Assignee
Деленекс Терапьютикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Деленекс Терапьютикс Аг filed Critical Деленекс Терапьютикс Аг
Publication of RU2008146922A publication Critical patent/RU2008146922A/ru
Application granted granted Critical
Publication of RU2460540C2 publication Critical patent/RU2460540C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2008146922/10A 2006-04-28 2007-04-27 Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk) RU2460540C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
US60/795,831 2006-04-28

Publications (2)

Publication Number Publication Date
RU2008146922A RU2008146922A (ru) 2010-06-10
RU2460540C2 true RU2460540C2 (ru) 2012-09-10

Family

ID=38515389

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008146922/10A RU2460540C2 (ru) 2006-04-28 2007-04-27 Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk)

Country Status (16)

Country Link
US (3) US7902340B2 (https=)
EP (2) EP2013236B1 (https=)
JP (2) JP5431920B2 (https=)
KR (1) KR101457228B1 (https=)
CN (1) CN101443361B (https=)
AU (1) AU2007246144B2 (https=)
BR (1) BRPI0710971A2 (https=)
CA (1) CA2650822C (https=)
DK (1) DK2013236T3 (https=)
ES (1) ES2547248T3 (https=)
IL (1) IL194752A0 (https=)
MX (1) MX2008013705A (https=)
NZ (1) NZ572248A (https=)
PL (1) PL2013236T3 (https=)
RU (1) RU2460540C2 (https=)
WO (1) WO2007124610A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710971A2 (pt) * 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
WO2015184231A2 (en) * 2014-05-30 2015-12-03 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
MY196631A (en) 2015-10-13 2023-04-24 Eureka Therapeutics Inc Antibody Agents Specific for Human Cd19 and uses Thereof
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
JP7654402B2 (ja) * 2018-02-09 2025-04-01 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
JPH1116250A (ja) * 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
ATE273323T1 (de) * 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
CA2412650C (en) 2000-06-14 2011-08-02 Georgetown University Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
JP2006508638A (ja) * 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
WO2006020684A2 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
BRPI0710971A2 (pt) * 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STOICA GE et al. "Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin". J Biol Chem. 2001 May 18; 276(20), с.16772-16779. STOICA GE et al. "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types". J Biol Chem. 2002 Sep 27; 277(39), с.35990-35998. AUF DER MAUR A, et al. "Antigen-independent selection of intracellular stable antibody frameworks". Methods. 2004 Oct; 34(2), с.215-224. *
РОЙТ А. и др. Иммунология. - М.: Мир, 2000, с.97-112. *

Also Published As

Publication number Publication date
RU2008146922A (ru) 2010-06-10
NZ572248A (en) 2011-08-26
JP5431920B2 (ja) 2014-03-05
JP2013226144A (ja) 2013-11-07
JP5911821B2 (ja) 2016-04-27
CA2650822C (en) 2017-03-14
AU2007246144B2 (en) 2012-12-06
CN101443361B (zh) 2015-08-19
JP2009535021A (ja) 2009-10-01
US20110159008A1 (en) 2011-06-30
EP2013236A1 (en) 2009-01-14
BRPI0710971A2 (pt) 2011-05-31
US9512411B2 (en) 2016-12-06
HK1124619A1 (en) 2009-07-17
IL194752A0 (en) 2011-08-01
AU2007246144A1 (en) 2007-11-08
CN101443361A (zh) 2009-05-27
DK2013236T3 (en) 2015-09-21
US20080118512A1 (en) 2008-05-22
MX2008013705A (es) 2008-11-06
CA2650822A1 (en) 2007-11-08
EP2013236B1 (en) 2015-06-17
EP2604627A1 (en) 2013-06-19
KR101457228B1 (ko) 2014-11-04
KR20080113261A (ko) 2008-12-29
US7902340B2 (en) 2011-03-08
US8945563B2 (en) 2015-02-03
ES2547248T3 (es) 2015-10-02
PL2013236T3 (pl) 2015-12-31
US20150203829A1 (en) 2015-07-23
WO2007124610A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
RU2460540C2 (ru) Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk)
TWI744242B (zh) Egfrviii及cd3抗體構築體
JP7011574B2 (ja) Ｆｌｔ３及びｃｄ３に対する抗体構築物
US11359021B2 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
KR20150063447A (ko) 알파-시누클레인을 인식하는 항체
KR20050049470A (ko) 항 수초 관련 당단백질 항체
MX2011000233A (es) Agentes de union del receptor notch1 y metodos para su uso.
CN102421802A (zh) 人源化的axl抗体
AU2019208793A1 (en) Anti-4-1BB antibody, antigen-binding fragment thereof and medical use thereof
KR20150013935A (ko) 트랜스포터에 대한 항체 및 이의 용도
CN113056486A (zh) 改善的抗flt3抗原结合蛋白
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
JP2022512672A (ja) アントラサイクリンを含む結合タンパク質－毒素融合体、および免疫腫瘍学的適用におけるその使用
TW201106971A (en) Antigen-binding proteins
WO2008131575A2 (en) Anti-alk antibodies suitable for treating metastatic cancers or tumors
EP4230652A1 (en) Anti-oscar antibody for preventing or treating osteoarthritis
KR101854529B1 (ko) 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
AU2012244351B2 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
CA3070085A1 (en) Antibodies to amyloid beta
WO2015138411A1 (en) Anti-fibulin-3 antibodies and uses thereof
HK1124619B (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
CA3232234A1 (en) Novel wnt agonist antibodies and therapeutic uses thereof
HK1078590A1 (zh) 新的抗igf-ir抗体及其应用
HK1078590B (en) Novel anti-igf-ir antibodies and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200428